留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?

陈文明

陈文明. 自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?[J]. 协和医学杂志, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007
引用本文: 陈文明. 自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?[J]. 协和医学杂志, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007
Wen-ming CHEN. Is Autologous Stem Cell Transplantation the Standard Treatment for Transplant-eligible Patients with Multiple Myeloma?[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007
Citation: Wen-ming CHEN. Is Autologous Stem Cell Transplantation the Standard Treatment for Transplant-eligible Patients with Multiple Myeloma?[J]. Medical Journal of Peking Union Medical College Hospital, 2018, 9(3): 224-227. doi: 10.3969/j.issn.1674-9081.2018.03.007

自体造血干细胞移植是适合移植的多发性骨髓瘤患者的标准治疗?

doi: 10.3969/j.issn.1674-9081.2018.03.007
详细信息
    作者简介:

    陈文明:电话:010-85231000, E-mail:13910107759@qq.com

  • 中图分类号: R733.3

Is Autologous Stem Cell Transplantation the Standard Treatment for Transplant-eligible Patients with Multiple Myeloma?

More Information
  • 摘要: 自体造血干细胞移植(autologous stem cell transplantation, ASCT)是多发性骨髓瘤的标准治疗策略之一。不论是传统药物时代, 还是新药时代, ASCT均作为多发性骨髓瘤治疗的重要手段之一。尽管文献报道ASCT可延长患者的无进展生存期, 但对总生存期的获益有待进一步探讨, 特别是高危患者, ASCT可能并不能使患者获益。此外, ASCT后的巩固、维持治疗对预后也至关重要, 且ASCT具有存在相关不良反应以及再发肿瘤的风险, 故ASCT用于多发性骨髓瘤治疗的价值仍有待商榷。
  • [1] Blokhin N, Larionov L, Perevodchikova N, et al.[Clinical experiences with sarcolysin in neoplastic diseases] [J]. Ann N Y Acad Sci, 1958, 68:1128-1132. doi:  10.1111/j.1749-6632.1958.tb42675.x
    [2] McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma[J]. Lancet, 1983, 2:822-824. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=6137651
    [3] Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma[J]. N Engl J Med, 1999, 341:1565-1571. doi:  10.1056/NEJM199911183412102
    [4] Orlowski RZ, Eswara JR, Lafond-Walker A, et al.Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor[J]. Cancer Res, 1998, 58:4342-4348. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM9766662
    [5] Orlowski RZ, Stinchcombe TE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies[J]. J Clin Oncol, 2002, 20:4420-4427. doi:  10.1200/JCO.2002.01.133
    [6] Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells[J]. Cancer Res, 2001, 61:3071-3076. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM11306489
    [7] Kumar SK, Callander NS, Alsina M, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15:230-269. doi:  10.6004/jnccn.2017.0023
    [8] Moreau P, San Miguel J, Sonneveld P, et al.Multiple myeloma:ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2017, 28:iv52-iv61. http://annonc.oxfordjournals.org/content/21/suppl_5/v155.full
    [9] Chng WJ, Dispenzieri A, Chim CS, et al.IMWG consensus on risk stratification in multiple myeloma[J]. Leukemia, 2014, 28:269-277. doi:  10.1038/leu.2013.247
    [10] Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma:guidelines from the mayo stratification for myeloma and risk-adapted therapy[J]. Mayo Clin Proc, 2017, 92:578-598. doi:  10.1016/j.mayocp.2017.01.003
    [11] Barlogie B, Attal M, Crowley J, et al.Long-term follow-up of autotransplantation trials for multiple myeloma:update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences[J]. J Clin Oncol, 2010, 28:1209-1214. doi:  10.1200/JCO.2009.25.6081
    [12] Porcher R, Lévy V, Fermand JP, et al. Evaluating high dose therapy in multiple myeloma:use of quality-adjusted survival analysis[J]. Qual Life Res, 2002, 11:91-99. doi:  10.1023/A:1015096313594
    [13] Facon T, Mary JY, Harousseau JL, et al. Front-line or rescue autologous bone marrow transplantation (ABMT) following a first course of high dose melphalan (HDM) in multiple myeloma (MM). Preliminary results of a prospective randomized trial (CIAM)protocol[J]. Blood, 1996, 88:2729.
    [14] Child JA, Morgan GJ, Davies FE, et al.High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma[J]. N Engl J Med, 2003, 348:1875-1883. doi:  10.1056/NEJMoa022340
    [15] Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma:final results of phase Ⅲ US intergroup trial S9321[J]. J J Clin Oncol, 2006, 24:929-936. doi:  10.1200/JCO.2005.04.5807
    [16] Rosiñol L, Pérez-Simón JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma[J]. Blood, 2008, 112:3591-3593. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=e3c0b876e7fe028ba2e016172004035e
    [17] Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma:a prospective evaluation of patients treated in the phase Ⅲ study HOVON 24 MM[J]. J Clin Oncol, 2003, 21:1728-1733. doi:  10.1200/JCO.2003.04.033
    [18] Palumbo A, Bringhen S, Petrucci MT, et al.Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70:results of a randomized controlled trial[J]. Blood, 2004, 104:3052-3057. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM15265788
    [19] Facon T, Mary JY, Hulin C, et al.Melphalan and predni-sone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06):a randomised trial[J]. Lancet, 2007, 370:1209-1218. doi:  10.1016/S0140-6736(07)61537-2
    [20] Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma:a systematic review and meta-analysis of randomized controlled trials[J]. Biol Blood Marrow Transplant, 2007, 13:183-196. doi:  10.1016/j.bbmt.2006.09.010
    [21] Etto LY, Morelli VM, Silva VC, et al. Autologous stem cell transplantation improves quality of life in economically challenged, Brazilian multiple myeloma patients[J]. Clinics (Sao Paulo), 2011, 66:1855-1859. http://europepmc.org/articles/PMC3203955/
    [22] Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma[J]. N Engl J Med, 2017, 376:1311-1320. doi:  10.1056/NEJMoa1611750
    [23] Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma[J]. Blood, 2012, 120:1067-1076. doi:  10.1182/blood-2012-01-405985
  • 加载中
计量
  • 文章访问数:  147
  • HTML全文浏览量:  5
  • PDF下载量:  201
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-07-25
  • 刊出日期:  2018-05-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!